Teva

A Palestinian manufacturer's own account. Founded in Birzeit in 1974, listed on the Palestine Exchange since 2005, operating four production sites and making about 270 pharmaceutical products across 16 production lines under roughly 170 brand names. Certified to ISO 9001 in 2001, ISO 14001 in 2004 and to World Health Organization good manufacturing practice standards in 2008. Supplies the Palestinian Ministry of Health, local and international healthcare organisations, pharmacies and doctors, and exports mainly to Algeria and eastern Europe.

A second Palestinian manufacturer's own account. Four manufacturing facilities across Palestine, Jordan and Algeria, producing generic medicines for local and export markets. Its Palestinian facility is certified for good manufacturing practice by the Palestinian Ministry of Health, holds ISO 9001 and ISO 14001, and received Jordan Food and Drug Administration GMP certification for its solid preparation lines in 2016.

Revenue of $4,142 million, down 1% in dollars and 3% in local currency on the same quarter of 2025. The International Markets segment, which contains Israel, rose 11% to $550 million. Net debt of $12.938 billion at 30 June 2026, against total debt of $16.593 billion and cash of $3.655 billion. Free cash flow $622 million, up 31%. Combined sales of Austedo, Ajovy and Uzedy rose 43% year on year.

The company's own annual report, filed with the US Securities and Exchange Commission on 3 February 2026. Records principal executive offices at 124 Dvora HaNevi'a Street, Tel Aviv, incorporation in Israel on 13 February 1944 as successor to Israeli corporations the oldest of which dates from 1901, and treats Israel inside the International Markets segment rather than as a reported segment of its own. International Markets operating income was $336 million in 2025 against $440 million in 2024.

Revenue of $17.3 billion for 2025, up 4% in dollars and 3% in local currency. Free cash flow $2.396 billion. Net debt $13.251 billion, down from $14.482 billion a year earlier. The three branded products Austedo, Ajovy and Uzedy passed $3 billion in combined sales, up 35% in local currency. Guidance for 2026 of $16.4-16.8 billion of revenue and $2.0-2.4 billion of free cash flow.

Reports the worldwide 'No Teva' campaign launched by Health Care Workers for Palestine and subsequently endorsed by the Palestinian-led BDS movement, with organising in Ireland, Belgium, Italy and Spain. Records that in Rovereto, Italy, the local authority asked pharmacies to display notices informing customers of their right to choose alternatives to Teva products, and that campaigners in Spain name Teva's affiliates Tevagen, Dalvur, Belmac and Ratiopharm.

About 470 staff at Beaumont Hospital in Dublin, and around 250 medical consultants across Ireland, backed the call for the Health Service Executive to stop buying Teva medicines where alternatives exist. Staff at the National Orthopaedic Hospital Cappagh had made the same request in September 2025. Teva is one of the HSE's largest suppliers of generic medicines.

The Danish asset management title reports that PKA Pension, P+ and AkademikerPension will no longer invest in Teva, citing the company's affiliation with the Israeli military and the risk of association with human rights violations. The full article is behind a subscription wall; the exclusions sit alongside broader Danish pension decisions during 2025 to exclude the State of Israel and state-controlled Israeli companies.

The UN Independent International Commission of Inquiry on the OPT concludes that Israeli authorities and security forces 'have committed and are continuing to commit' acts of genocide against Palestinians in Gaza, and that Israel 'bears responsibility for the failure to prevent genocide, the commission of genocide and the failure to punish genocide' (A/HRC/60/CRP.3, paras. 252 and 255).

Teva's own answer to the boycott calls, recorded by the Business and Human Rights Resource Centre. The company said that 'any boycott on Teva may impose a risk on the health and wellbeing of those patients, the healthcare systems we serve, our global workforce and their families', that it adheres to the 'highest standards in ethics and business practices', and that it is committed to ensuring its medicines remain available to patients 'regardless of their religion, beliefs, or ethnicity'. It also said its Irish activity contributed $226 million to the economy and that generic substitution had saved the Irish health system more than EUR 1.5 billion over a decade.

Fifty-seven consultants at Children's Health Ireland wrote to the Health Service Executive asking it to 'discontinue the procurement and use of pharmaceuticals manufactured by Teva where viable alternatives exist', on the ground that the company contributes to the economy of a state under investigation for genocide. The HSE said its chief executive Bernard Gloster had received the letter and was reviewing it, and that its procurement must comply with government guidelines and EU directives.

Dutch campaign research documenting Teva's support for the Israeli armed forces after October 2023: donations of medicines and medical supplies, participation in the 'Adopt-a-Battalion' scheme, and collection points at five Israeli sites through which employees gathered about 1.5 tonnes of equipment for army units by the end of October 2023.

The Norwegian hospital procurement agency's own decision, published 20 March 2025 and last updated 30 June 2025. On the basis of the KPMG research it concluded that Teva does not contribute to maintaining Israel's unlawful presence in Palestinian territory, and did not recommend terminating contracts with Teva Norway AS. It recorded that from 1 May 2025 only five active pharmaceutical substances marketed by Teva were expected to be supplied under agreement, worth about NOK 20 million a year at net purchase price, and that certain audit findings would be followed up with the supplier. The review followed the Norwegian government's strengthened warning of 17 October 2024 to Norwegian businesses against trade that helps maintain the occupation.

The single most detailed independent examination of this company, commissioned on 21 November 2024 by Norway's hospital procurement agency and researched in English, Hebrew and Arabic. On the occupied territory it found that Teva's Israeli facilities - a raw materials plant at Neot Hovav, manufacturing and R&D at Kfar Saba and a Shoham logistics centre run by its subsidiary Salomon, Levin & Elstein - are not in occupied territory, and that 'if Teva continues to have a physical presence in the OPT, this is not information that is available in open sources'. It records that Teva's subsidiary MBT Biological Laboratories was reported by Gush Shalom to have moved from the Atarot industrial zone in occupied East Jerusalem to Beit Shemesh in 2016, that the Shoham landlord Amot Investments also lists an industrial estate in the settlement of Ariel among its assets, and that a Teva job advertisement listed Modi'in-Makkabim-Re'ut, which the EU treats as partly settlement, among five possible locations. On the military it concludes: 'Teva appears to be an active supporter of the IDF', citing the September 2024 Ynet interview with Teva Israel's general manager, employee equipment collections, participation in the 'Adopt-a-Battalion' donor scheme at about $27,000 a year for three years, and the chief executive of Teva's logistics subsidiary serving in Gaza, whose brigade he said 'received deliveries of equipment collected by Teva workers for us'. On the Palestinian market it finds the evidence 'mixed and inconclusive'. It also records more than $6 billion of US penalties and settlements since 2020 and a $503 million EU fine in 2024. The report says it is current as of 19 December 2024 only.

Teva's own announcement that it will pay the Israel Tax Authority $750 million in instalments between 2024 and 2029 to resolve all pending litigation over the tax years 2008-2020, and will in addition pay 5-7% of any dividends or share repurchases as corporate tax, up to a maximum of about $500 million.

Breaks the settlement into its parts: $500 million is tax on retained profits arising from Teva's classification as an approved enterprise under Israel's Encouragement of Capital Investment Law, and $250 million relates to a dispute over allowable expenses. Payments begin with $50 million in 2024 followed by annual instalments of $140-150 million.

More than 30 protesters blocked a Teva facility in the UK for around four hours, carrying banners reading 'Boycott Teva Pharma'. An early instance of the direct-action strand of the campaign in Britain, ahead of the health-worker organising that followed in Ireland and continental Europe.

Teva's chief executive said about 10% of the company's Israeli workforce had been called up as army reservists and that Israeli production and distribution were largely unaffected. The article also reports a senior Teva executive continuing corporate duties while serving in Gaza.

A study by the Ramallah research institute on the Palestinian pharmaceutical sector. It finds that Palestinian manufacturers meet 55% of local demand for pharmaceuticals, that around half the sector's workforce is skilled and educated, and that local producers face 'stiff competition in the local market from Israeli and Egyptian drug companies' and must 'unfairly compete with drugs smuggled from Israel to the West Bank'. It calls on Palestinian public agencies, physicians and pharmacists to support the sector, and on the public sector to make registration of locally produced medicines easier. KPMG cites a further MAS finding that imports of Israeli pharmaceutical products to Palestine fell from 34% to 20% of the market, the difference absorbed by Palestinian products.

Study by Yuval Neev and Daniel Friman, published May 2014 and covering 2003-2012. It found that in the years it examined Teva's contribution to GDP was 'about one tenth of the total industry', with a total economic multiplier of 1.98, a GDP multiplier of 1.72 and an employment multiplier of 5.53. The figures describe the decade to 2012 and predate Teva's restructuring, its 2016 acquisition of Actavis Generics and the reductions in its Israeli workforce since.

The Israeli research centre's company entry, filed under Economic Exploitation and Palestinian Captive Market. It records Teva's dominant position in the distribution of healthcare products in Israel, and states that Teva's agents 'do not have to amend any of their products in order to sell them in the OPT' and face minimal competition from Palestinian manufacturers because of Israeli regulatory restrictions. The page carries a validity date of 22 July 2012 and has not been revalidated since; KPMG noted in December 2024 that later claims about Teva and the Palestinian market largely trace back to it.

The underlying study. It argues that the Paris Protocol subordinates Palestinian pharmaceutical regulation to Israeli customs law, so that medicines imported to the occupied territory must first be registered in Israel; that Israel blocks bulk Palestinian pharmaceutical exports through Ben Gurion airport and imposes licensing requirements; and that Israeli producers including Teva therefore 'enjoy easy access to the Palestinian market, free of customs and checkpoint disturbances'. It puts the occupied territory's pharmaceutical market at 50% Palestinian manufacturers, 35% Israeli and 15% other imports, on an interview with the Union of Palestinian Pharmaceutical Manufacturers.